United Kingdom

People: Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

16 Aug 2019
Change (% chg)

$1.60 (+2.83%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hepner, Adrian 

Dr. Adrian J. Hepner, M.D. Ph.D, is Executive Vice President, Chief Medical Officer of Eagle Pharmaceuticals, Inc.Since January 2016, and previously served as our Executive Vice President, Clinical Research, Medical & Regulatory Affairs from January 2015 to January 2016. Dr. Hepner has over 25 years of experience in U.S. and international clinical research and drug development. Included in his experience is the development and implementation of the clinical and regulatory strategy for a number of products from early stage development through successful New Drug Application and European Union regulatory filings. After receiving his M.D. degree, Dr. Hepner completed visiting research physician experiences in the Department of Psychiatry at Harvard Medical School, the Department of Neurology at the National Institute of Mental Health, and a post-doctoral fellowship in neuropharmacology at the University of Ottawa. Additionally, he spent 17 years in neuropsychiatry private practice and participated in multiple clinical research studies. Dr. Hepner's pharmaceutical industry experience includes over 15 years of progressively increasing drug development responsibilities. He had a leading role in the regulatory and clinical activities for FDA approval of the first product for pseudobulbar affect, as well as the successful completion of placebo-controlled studies in other indications. Most recently, between July 2013 and December 2014, Dr. Hepner held the role of vice president of clinical research and medical affairs at BioDelivery Sciences International (BDSI), where he led the regulatory review process for the first buccal film approved for the maintenance treatment of opioid dedependence and had a critical role in its commercial launch. Prior to BDSI, in 2012, Dr. Hepner was senior medical director at UCB BioSciences, Inc., where he was responsible for global development projects in the central nervous system therapeutic area. He was also vice president of clinical research at Avanir Pharmaceuticals, from 2006 to 201

Basic Compensation

Total Annual Compensation, USD 424,360
Restricted Stock Award, USD 1,343,970
Long-Term Incentive Plans, USD --
All Other, USD 1,366,510
Fiscal Year Total, USD 3,134,840

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Graves


David Pernock


Scott Tarriff


Pete Meyers


Adrian Hepner


Douglas Braunstein

As Of  31 Dec 2018